On May 19, 2006 the FDA published a notice soliciting comments on the burden and utility of collecting drug adverse event information.

The AVMA is committed to the continuing availability of medicinal products that are pure, safe, potent and efficacious for animals. The AVMA encourages continued development and strengthening of adverse event reporting systems. This includes continued collaboration with constituent professional organizations, industry organizations, government entities and other stakeholders.